曲拉西利联合化疗治疗广泛期小细胞肺癌1例并文献复习

doi:10.3969/j.issn.1004-583X.2025.04.011

摘要/Abstract

摘要：

目的探讨曲拉西利联合化疗对广泛期小细胞肺癌(extensive small cell lung cancer, ES-SCLC)患者的治疗效果。方法回顾性分析西安交通大学第一附属医院收治的接受曲拉西利联合化疗治疗的ES-SCLC患者1例,并复习相关文献。结果患者为56岁女性,入院诊断为左肺小细胞肺癌(广泛期)、大气道狭窄、Ⅰ型呼吸衰竭,接受抢救性化疗后出现重度骨髓抑制,给予药物及输血治疗11 d后逐渐恢复。在后续5个周期化疗前联合曲拉西利,未再发生重度骨髓抑制,顺利完成化疗。结论在ES-SCLC患者接受化疗前4 h内给予曲拉西利,可有效降低患者骨髓抑制的程度,缩短骨髓抑制的持续时间,增加患者对化疗药物的耐受性,且对疗效无负面影响,建议临床推广。

关键词: 小细胞肺癌, 曲拉西利, 化疗, 骨髓抑制

Abstract:

Objective To study the effect of trilaciclib combined with chemotherapy on extensive small cell lung cancer (ES-SCLC). Methods A case of ES-SCLC patient treated with trilaciclib combined with chemotherapy in the First Affiliated Hospital of Xi'an Jiaotong University was retrospectively reviewed, and the related literatures were reviewed. Results The 56-year-old female patient was diagnosed with ES-SCLC of the left lung, large airway stenosis, and type I respiratory failure. She developed severe myelosuppression after receiving rescue chemotherapy, and gradually recovered after 11 days of drug administration and blood transfusion. After 5 cycles of chemotherapy combined with trilaciclib, severe myelosuppression was not reported, and chemotherapies were successfully completed. Conclusion The administration of trilaciclib within 4 h before chemotherapy in ES-SCLC patients can effectively reduce the degree of bone marrow suppression, shorten the duration of bone marrow suppression, and increase the tolerance to chemotherapy drugs without adverse impacts on the efficacy, suggesting clinical promotion.

Key words: small cell lung carcinoma, trilaciclib, chemotherapy, myelosuppression

中图分类号:

R734.1

王银峰, 李满祥. 曲拉西利联合化疗治疗广泛期小细胞肺癌1例并文献复习[J]. 临床荟萃, 2025, 40(4): 355-359.

Wang Yinfeng, Li Manxiang. Trilaciclib combined with chemotherapy in the treatment of extensive-stage small cell lung cancer: A case report and literature review[J]. Clinical Focus, 2025, 40(4): 355-359.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://lchc.magtechjournal.com/CN/10.3969/j.issn.1004-583X.2025.04.011

https://lchc.magtechjournal.com/CN/Y2025/V40/I4/355

图/表 4

参考文献 23

[1]	Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Centr, 2024, 4(1): 47-53.
[2]	Oronsky B, Reid TR, Oronsky A, et al. What's new in SCLC? A review[J]. Neoplasia, 2017, 19(10): 842-847. doi: S1476-5586(17)30270-1 pmid: 28888101
[3]	Saltos A, Shafique M, Chiappori A. Update on the biology, management, and treatment of small cell lung cancer (SCLC)[J]. Front Oncol, 2020, 10:1074. doi: 10.3389/fonc.2020.01074 pmid: 32766139
[4]	Epstein RS, Aapro MS, Basu Roy UK, et al. Patient burden and real-world management of chemotherapy-induced myelosuppression: Results from an online survey of patients with solid tumors[J]. Adv Ther, 2020, 37(8): 3606-3618. doi: 10.1007/s12325-020-01419-6 pmid: 32642965
[5]	Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy[J]. Oncology (Williston Park), 2015, 29(4): 282-294.
[6]	Aapro M, Beguin Y, Bokemeyer C, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines[J]. Ann Oncol, 2018, 29(Suppl 4): iv96-iv110.
[7]	Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines[J]. Ann Oncol, 2016, 27(Suppl 5): v111-v118.
[8]	秦叔逵, 马军. 中国临床肿瘤学会(CSCO)肿瘤放化疗相关中性粒细胞减少症规范化管理指南(2021)[J]. 临床肿瘤学杂志, 2021, 26(7):638-648.
[9]	马军, 王杰军, 张力, 等. 肿瘤相关性贫血临床实践指南(2015-2016版)[J]. 中国实用内科杂志, 2016, 36(S1):1-21.
[10]	史艳侠, 邢镨元, 张俊, 等. 中国肿瘤化疗相关性血小板减少症专家诊疗共识(2019版)[J]. 中国肿瘤临床, 2019, 46(18):923-929.
[11]	吴育锋, 余利蒙, 赵玉华, 等. 小细胞肺癌化疗相关骨髓抑制的研究进展[J]. 中国新药杂志, 2023, 32(23):2347-2353.
[12]	Dhillon S. Trilaciclib: First approval[J]. Drugs, 2021, 81(7): 867-874.
[13]	抗肿瘤药物引起骨髓抑制中西医结合诊治专家共识[J]. 临床肿瘤学杂志, 2021, 26(11):1020-1027.
[14]	Banys-Paluchowski M, Krawczyk N, Paluchowski P. Cyclin-dependent kinase 4/6 inhibitors: What have we learnt across studies, therapy situations and substances[J]. Curr Opin Obstet Gynecol, 2019, 31(1):56-66.
[15]	Daniel D, Kuchava V, Bondarenko I, et al. Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled phase II trial[J]. Int J Cancer, 2021, 148(10): 2557-2570.
[16]	Hart LL, Ferrarotto R, Andric ZG, et al. Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: Results from a randomized, double-blind, placebo-controlled phase II study[J]. Adv Ther, 2021, 38(1): 350-365. doi: 10.1007/s12325-020-01538-0 pmid: 33123968
[17]	Weiss JM, Csoszi T, Maglakelidze M, et al. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: A phase Ib/randomized phase II trial[J]. Ann Oncol, 2019, 30(10): 1613-1621. doi: S0923-7534(19)60981-6 pmid: 31987452
[18]	徐华, 李封, 王娟, 等. 曲拉西利联合免疫联合化疗一线治疗晚期非小细胞肺癌1例及文献分析[J]. 中国新药杂志, 2024, 33(11):1126-1132.
[19]	严京泽, 陈慧, 葛小林, 等. 曲拉西利联合免疫联合化疗治疗晚期食管癌1例及文献分析[J]. 中国新药杂志, 2023, 32(23):2370-2374.
[20]	袁静, 卢卫平, 肖国栋, 等. 曲拉西利联合拓扑替康二线治疗广泛期小细胞肺癌1例及文献分析[J]. 中国新药杂志, 2023, 32(23):2360-2365.
[21]	Tan AR, Wright GS, Thummala AR, et al. Trilaciclib prior to chemotherapy in patients with metastatic triple-negative breast cancer: Final efficacy and subgroup analysis from a randomized phase II study[J]. Clin Cancer Res, 2022, 28(4):629-636.
[22]	Lai AY, Sorrentino JA, Dragnev KH, et al. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy[J]. J Immunother Cancer, 2020, 8(2):e000847.
[23]	Deng J, Wang ES, Jenkins RW, et al. CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation[J]. Cancer Discov, 2018, 8(2): 216-233. doi: 10.1158/2159-8290.CD-17-0915 pmid: 29101163

周期(时间)	用药方案	抗肿瘤疗效	骨髓抑制分级
第1周期(2023-12-30)	依托泊苷145 mg(d1~3)+顺铂40 mg(d1~2)+顺铂30 mg(d3)	-	Ⅳ级
第2周期(2024-01-23)	曲拉西利300mg(d1~2)+依托泊苷110 mg(d1~3)+顺铂40 mg(d1~2)	PR	Ⅲ级
第3周期(2024-02-21)	曲拉西利300 mg(d1~2)+依托泊苷110mg(d1~3)+顺铂40 mg(d1~2)	-	Ⅱ级
第4周期(2024-03-13)	曲拉西利300 mg(d1~2)+依托泊苷110mg(d1~3)+顺铂40 mg(d1~2)	PR	Ⅰ级
第5周期(2024-04-24)	曲拉西利300mg(d1~2)+依托泊苷110 mg(d1~3)+顺铂40 mg(d1~2)	-	Ⅱ级
第6周期(2024-05-17)	曲拉西利300 mg(d1~2)+依托泊苷110mg(d1~3)+顺铂40 mg(d1~2)	PR	Ⅰ级

周期(时间)	用药方案	抗肿瘤疗效	骨髓抑制分级
第1周期(2023-12-30)	依托泊苷145 mg(d1~3)+顺铂40 mg(d1~2)+顺铂30 mg(d3)	-	Ⅳ级
第2周期(2024-01-23)	曲拉西利300mg(d1~2)+依托泊苷110 mg(d1~3)+顺铂40 mg(d1~2)	PR	Ⅲ级
第3周期(2024-02-21)	曲拉西利300 mg(d1~2)+依托泊苷110mg(d1~3)+顺铂40 mg(d1~2)	-	Ⅱ级
第4周期(2024-03-13)	曲拉西利300 mg(d1~2)+依托泊苷110mg(d1~3)+顺铂40 mg(d1~2)	PR	Ⅰ级
第5周期(2024-04-24)	曲拉西利300mg(d1~2)+依托泊苷110 mg(d1~3)+顺铂40 mg(d1~2)	-	Ⅱ级
第6周期(2024-05-17)	曲拉西利300 mg(d1~2)+依托泊苷110mg(d1~3)+顺铂40 mg(d1~2)	PR	Ⅰ级